Newron Announces 2025 Results and 2026 Outlook

Newron Pharmaceuticals S.p.A., a company specializing in neurological therapies, presented its financial results for 2025 and offered projections for 2026. The company, noted for its work on the drug evenamide aimed at treating schizophrenia, highlighted several milestones over the past year.

In 2025, pivotal trials for evenamide progressed with regulatory approvals and the initiation of critical studies, ENIGMA-TRS 1 and 2. Additionally, a new patent granted by the European Patent Office promises extended market exclusivity until 2044.

Financially, Newron posted a net loss of EUR 13.2 million for 2025, a shift from the previous year’s profit. Despite a drop in license income, cash reserves increased significantly, supporting the company’s R&D efforts. Looking forward, Newron plans to sustain its momentum by advancing the ENIGMA-TRS trials and exploring new market opportunities.